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 CURRENTOPINION The management of urinary incontinence in the
male neurological patient
Ulrich Mehnert and Thomas M. Kessler
Purpose of review
Urinary incontinence in male neurological patients is a very frequent problem but treatment remains
challenging. Thus, we summarize and highlight the latest developments in the management of urinary
incontinence in this specific patient population.
Recent findings
Intermittent self-catheterization, antimuscarinics, intradetrusor injections with onabotulinumtoxinA,
augmentation cystoplasty, urinary diversion, and artificial urinary sphincter are the cornerstones of the
armamentarium for treating neurogenic urinary incontinence. However, with the exception of
onabotulinumtoxinA intradetrusor injections, level of evidence is often low and male-specific outcomes are
virtually not available.
Alternative conservative and/or minimally invasive procedures such as neuromodulation techniques and
suburethral suspension devices provide promising data with apparently good safety and tolerability but still
insufficient evidence lacking randomized control trials.
Summary
Standard options for treatment of urinary incontinence in neurological patients remain largely unchanged.
Alternative treatment options, especially of conservative or minimally invasive character, have the potential
to further broaden the therapeutic spectrum.
While a higher level of evidence is needed to assess the potential of such therapeutic approaches,
randomized controlled trials in the male neurological population present a challenge. To truly advance
treatment of urinary continence in male neurological patients, well-designed, multicenter studies are
warranted.
Keywords
male neurological patients, neurogenic detrusor overactivity, neurogenic sphincter insufficiency, urinary
incontinence, urinary incontinence therapy
INTRODUCTION
Urinary incontinence in neurological patients is a
very frequent [1] and debilitating condition result-
ing from the profound alterations of lower urinary
tract (LUT) control and function caused by the
neurological disorder. It should be implicitly con-
sidered that in neurological patients LUT symptoms
such as urgencymay be reduced or absent because of
sensory deficits, and that urinary incontinence is
often the ‘only’ apparent symptom of relevant LUT
dysfunction requiring further specialized investi-
gation [2
&&
].
Therefore, it is of utmost importance not only to
appropriately differentiate between the different
types of urinary incontinence but also to understand
the underlying neurological cause as it significantly
influences the choice of treatment. Urinary incon-
tinence related to neurogenic detrusor overactivity
(NDO) requires a completely different manage-
ment than urinary incontinence related to isolated
neurogenic sphincter insufficiency. Neglect of this
principle may result not only in insufficient and
inaccurate treatment but also in significant harm of
the patient.
The scope of this article is to review themanage-
ment of urinary incontinence in male neurological
patients. However, data specifically considering the
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male neurological population is very rare so that we
took into account neurological patients in general
and referred tomale-specific data whenever possible.
MANAGEMENT OPTIONS FOR URINARY
INCONTINENCE IN MALE NEUROLOGICAL
PATIENTS
As therapeutic principles in male neurological
patients largely depend on the underlying cause
of urinary incontinence, that is, mainly NDO and/
or neurogenic sphincter insufficiency, the current
armamentarium focuses on treating either cause or
both in mixed forms. However, prior to the appli-
ance of any form of subvesical obstruction with the
intention to treat neurogenic stress urinary incon-
tinence (SUI), that is, suburethral slings, adjustable
continence devices, and artificial urethral sphincter,
it is mandatory to first adequately treat detrusor
overactivity or reduced bladder compliance as oth-
erwise increased storage pressures can jeopardize
upper urinary tract function.
An often-underestimated or neglected problem
in neurological patients is concomitant problems
with defecation that can interfere with LUT function
and should be addressed before or concomitantly
with any medical or surgical urinary incontinence
therapy.
Behavioral therapy and pelvic floor exercises
Although specific studies on behavioral treatment
(aiming to adapt drinking and voiding habits) in
male neurological urinary incontinence are lacking,
it should be part of the first-line treatment.
Behavioral regimens have to be adapted to the
individual abilities and needs of the patients and
suit best for patients in whom voiding function is
intact and urinary incontinence is mainly due to
impaired bladder sensation, cognitive, or motor
deficits. However, in such cases, caregivers need to
provide additional support.
Pelvic floor muscle training (PFMT) has been
mainly explored within multiple sclerosis (MS)
populations with predominantly female patients
[3]. In men, PFMT is primarily used to treat post-
prostatectomy SUI. Nevertheless, PFMT has been
shown to be beneficial in the treatment of both,
stress and urgency urinary incontinence [4]. How-
ever, to be successful, voluntary pelvic floor sensor-
imotor control must be at least partly intact which
can be a limiting factor in many neurological
patients.
Catheters
Intermittent self-catheterization (ISC) can improve
urinary incontinence and is the gold standard in the
management of neurogenic voiding dysfunction due
to detrusor sphincter dyssynergia or underactive/
acontractile detrusor. Although newer data and
expert panels are in favor of single-use hydrophilic
catheters in an aseptic or clean manner [5–8], the
level of evidence is still low resulting in an ongo-
ing debate on the optimal technique (sterile vs.
clean vs. aseptic; single-use vs. reuse) and catheter
type (hydrophilic vs. noncoated catheters) regard-
ing the rate of UTI, urethral lesions, cost-effective-
ness, and health-related quality of life (HRQoL)
[9
&&
,10–13].
Recent articles focused on the impact of ISC
on HRQoL [14], patient’s adherence to ISC [15
&
],
and preferences regarding catheter design [13,16]
including male-specific data [17,18].
Indwelling catheters can be effective in treating
urinary incontinence and especially suprapubic
catheters might be an option for highly selected
populations, such as tetraplegic patients [19]. How-
ever, indwelling catheters are not recommended for
routine long-term treatment because of the associ-
ated complications such as acute and chronic UTI,
stone formation, urinary leakage/incontinence,
erosion of meatus and urethra, fistula formation,
reduction in bladder capacity, and compliance (with
continuous drainage) [20,21,22
&&
].
Condom catheters [23] or other external appli-
ances such as drip collectors can help to control
urinary incontinence and make it socially more
acceptable.
KEY POINTS
 Treatment of urinary incontinence in male neurological
patients is challenging and often requires multimodal
therapy.
 Intermittent self-catheterization, antimuscarinics,
intradetrusor onabotulinumtoxinA injections,
augmentation cystoplasty, urinary diversion, and
artificial urinary sphincter are still the cornerstones of
urinary incontinence treatment in neurological patients.
 With the exception of onabotulinumtoxinA intradetrusor
injections, the level of evidence of many therapy
options for urinary incontinence due to neurogenic
detrusor overactivity and/or neurogenic sphincter
insufficiency is low.
 Current findings are mainly from multiple sclerosis and
spinal cord injury patients without gender-specific
outcomes limiting generalization of the results.
 RCTs are urgently needed, especially for upcoming and
promising treatment options, such as neuromodulation
techniques and suburethral suspension devices.
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Drugs
The first-line drug treatment for NDO and sub-
sequent urinary incontinence are antimuscarinics,
that is, oxybutynin, trospium chloride, tolterodine,
solifenacin, darifenacin, propiverine, and fesotero-
dine. Efficacy and safety of antimuscarinics are well
described for the non-neurogenic overactive bladder
population [24,25] but less conclusive for patients
with NDO because of a limited and very hetero-
geneous body of studies [26
&&
]. Nevertheless, anti-
muscarinics were demonstrated to significantly
improve patient-reported and urodynamic outcome
compared with placebo in the NDO population
[26
&&
]. However, a significant improvement of uri-
nary incontinence could not be demonstrated
[26
&&
]. The current results are mainly based on data
from spinal cord injury (SCI) or MS populations and
conclusions cannot be readily extended to other
neurological diseases, such as stroke or Parkinson’s
disease. Furthermore, effects on bladder compli-
ance, upper urinary tract function, and HRQoL were
usually not assessed and long-term data of antimus-
carinics in neurological patients are very limited
[26
&&
,27].
Although some large clinical trials could dem-
onstrate statistically significant efficacy differences
between several antimuscarinics, such differences
seem to remain rather marginal from a clinical
viewpoint and could not be demonstrated for
the NDO population [26
&&
,28]. Differences in the
safety and tolerability profiles seem to be more
relevant and should be considered when choosing
an antimuscarinic drug for a specific patient,
especially considering central nervous side-effects
[28,29].
Dose-escalating mono or combination therapy
can be an option for NDO patients, requiring higher
doses as urodynamic parameters could be signifi-
cantly improved comparedwith standard dose treat-
ment [27,30]; however, high-evidence level studies
are lacking.
A recent, but rather small, study comparing the
immediate and extended release forms of propiver-
ine for NDO demonstrated better continence rates
using the extended release form [31]. Transdermal
or intravesical antimuscarinic applications are
alternative options that may help to increase bio-
avalability and reduce adverse events due to the
circumvention of the intestinal first pass meta-
bolism [32], but clinical data for the use in adult
NDO patients are still very limited.
Other drugs, such as phosphodiesterase inhibi-
tors or beta-adrenergic receptor agonists, seem to
become future alternatives [33,34] but have not yet
been investigated for the treatment of urinary
incontinence in neurological patients.
External neuromodulation
Of the different potential treatment modalities
available, tibial nerve stimulation either percutane-
ously (PTNS) or transcutaneously (TTNS) seems to
be the currently most promising and investigated
method. However, themainstay of available data are
from non-neurogenic overactive bladder patients
[35,36], but some recent studies also provided data
from neurological patients, that is, MS and Parkin-
son’s disease [37–44]. However, randomized con-
trolled trials (RCTs) are lacking for PTNS and TTNS
in the neurological population, and there are cur-
rently no long-term data or systematic data on
HRQoL available. Nevertheless, the benefits of PTNS
and TTNS are clearly the almost inexistent adverse
events and the noninvasiveness that allows per-
formance of diagnostic measures, such as repeated
MRI or home-based therapy (for TTNS).
Intradetrusor injections with botulinum toxin
On the basis of the results of the two recent Phase III
studies [45,46], intradetrusor injections using
onabotulinumtoxinA received Food and Drug
Administration approval in 2011 for the treatment
of urinary incontinence due to NDO in adults who
have an inadequate response to or are intolerant
of antimuscarinics. Intradetrusor injections with
botulinum toxin have been demonstrated to be safe,
well tolerated and to significantly improve urody-
namic parameters [47
&&
,48], reduce LUT symptoms
[47
&&
], and improve quality of life [49
&
,50]. Daily
urinary incontinence episodes can be reduced by
63% [47
&&
]. These effects seem to occur regardless of
concomitant antimuscarinics or neurological dis-
order, that is, MS or SCI [51]. However, data on
the use of intradetrusor botulinum toxin injections
in neurological patients other than SCI and MS are
scarce but there may be an indication [52].
Injections require a cystoscopic (rigid or flexible)
intervention that needs to be repeated every
6–9 months [53]. The procedure can be performed
in local anesthesia in most NDO patients. There is,
however, still controversy about the best technique.
Long-term data confirm the efficacy of onabo-
tulinumtoxinA beyond multiple intradetrusor
injections [54,55
&
], and cost-effectiveness seems to
be superior to best supportive care [56
&
]. If the
durability of onabotulinumtoxinA is greater than
5 months, intradetrusor injections seem to be more
cost-effective in the treatment of refractory NDO
than augmentation cystoplasty [57].
Permanent neuromodulation with implanted
electrodes
Initially, considered as unsuitable for the treatment
of LUT dysfunction in neurological patients due
Male incontinence
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to the impaired neuronal innervation, sacral
neuromodulation (SNM) has yet been demonstrated
to be a promising treatment option for NDO [58,59].
However, there is a lack of RCTs, and it is unclear
which neurological patient is most suitable for SNM
[58].
Remarkably, early bilateral SNM during the
phase of spinal shock phase could prevent NDO
and subsequent urinary incontinence in complete
SCI patients [60]. However, long-term results are
pending and the exact mechanism of action is not
well understood [61]. Nevertheless, as the method
is generally appealing because of its minimally
invasive and fully reversible technique, well
designed and adequately powered studies are highly
warranted.
Sacral deafferentation with or without
anterior root stimulator
This technique, also known as posterior rhizotomy,
has to be strictly distinguished from the afore-
mentioned SNM as sacral deafferentation is a
specialized surgical intervention that aims to abol-
ish NDO by transection of the afferent part of the
sacral reflex arc and is not reversible. Although
highly effective with up to 83% continence rates
[62], if complete transection of the sacral roots S2-S5
can be achieved, it is preserved for a highly selected
and well informed group of SCI patients who accept
the inevitable and permanent loss of any potentially
preserved sensation of the pelvis and lower limbs
and sexual function (e.g., reflex erections) [63]. In
combination with a sacral anterior root stimulator
(Finetech-Brindley bladder stimulation system)
patients can regain control of micturition and even
improve erectile and defecation function. An
additional benefit is that sacral deafferentation
can effectively abolish autonomic dysreflexia.
However, this procedure is nowadays less fre-
quently performed because of effective but less-inva-
sive alternatives, such as onabotulinumtoxinA
intradetrusor injections. Thus, new data are scarce.
One current retrospective study is available reporting
continence rates of 23% 15 years after sacral deaf-
ferentation and anterior root stimulator implan-
tation but also 84 cases of complications requiring
surgical intervention among 137 patients [64].
Augmentation cystoplasty
Although there are no RCT, augmentation cysto-
plasty is a recommended and established treatment
option for intractable urinary incontinence due to
NDO but requires major abdominal surgery with
interposition of an intestinal segment (usually
ileum) into the bladder and/or partial replacement
of bladder by an intestinal substitute, and should be
preserved for patients in whom conservative or less-
invasive treatment options failed to achieve an
adequate level of continence [65,66]. Importantly,
this treatment should only be offered to patients
who are able and willing to perform ISC. Augmen-
tation cystoplasty can be combined with a conti-
nent catheterizable cutaneous urinary diversion to
facilitate ISC in patients with limited dexterity.
Recent long-term data confirm previous data on
efficacy demonstrating sustained improvements
in both, urodynamic parameters and symptoms
[67–70].
A less-invasive version of bladder augmentation
is detrusor myectomy (autoaugmentation) with
lower surgical burden and complication rates, but
efficacy seems to be inferior to augmentation cys-
toplasty [71–73].
Urinary diversion
In highly selected patients cystectomy with urinary
diversion becomes necessary. Cystectomy in con-
trast to augmentation cystoplasty requires the reim-
plantation of the ureters, which basically implies the
risk of ureteral stenosis.
For continent urinary diversion different tech-
niques have been described [74,75]. Regular ISC is
required subsequently and specific complications
include stomal stenosis, channel leakage, false pas-
sage, and stomal prolapse [75,76]. However, there is
less alteration of body appearance than with incon-
tinent diversion that is usually indicated if ISC is
impossible or patient compliance is inadequate.
A recent case series in MS patients with
advanced refractory NDO demonstrated an effective
treatment of LUT dysfunction and associated pro-
blems with an improvement in HRQoL following
incontinent urinary diversion [77]. However, the
complication rate was high (55%) and the authors
consider urinary diversion as an effective but rather
last resort treatment option for neurogenic urinary
incontinence.
Bulking agents
Although bulking agents have been mainly used for
the treatment of SUI in women, there are also stud-
ies in men with rather discouraging results, especi-
ally in the long term [78,79]. RCT are lacking and
from the available data, bulking agents cannot be
considered a durable treatment especially for more
severe forms of SUI, which may be the reason that
there are no current data in adult male neurological
patients.
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Suspension therapy
Suburethral slings or tapes become more and more
popular for the treatment ofmale SUI as aminimally
invasive option, and different types have been intro-
duced with success rates of 54–80% [80]. In male
patients with neurogenic SUI mainly autologous
fascia slings, often in combination with bladder aug-
mentation, have been investigated predominantly in
pediatric populations but also in adults, demonstrat-
ing favorable results and low complication rates
[81–83]. Synthetic tapes are up-to-date rarely inves-
tigated inmaleneurological patients.Currently, only
one small study presents promising data from a
mixed adult and pediatric male neurological popu-
lation treated with the AdVance sling [84]. RCT and
data on long-term follow-up are lacking.
Implants for stress urinary incontinence
Adjustable periurethral balloons might be an option
in highly selected patients, but there is only one
study in a mixed population of patients with neuro-
genic SUI demonstrating rather fair results [85].
The Artificial Urinary Sphincter (AUS) is the gold
standard for the treatment of SUI and has also been
investigated in the adult male neurological popu-
lation demonstrating a high efficacy of 23–100%
(mean 70%) continent patients [83]. However, fre-
quent complications are erosion, infection, and
mechanical/device-related failure that cause a re-
operation rate for revisions and/or explantations
of 7–100% [83]. Comparing complication rates
between neurogenic and non-neurogenic patients
revealed that patients with neurogenic SUI tend to
have more frequently complications that were not
related to mechanical or device-related failure [86].
A recent study suggested a less costly and less
fragile alternative for SCI patients replacing the
pump with a subcutaneous port to adjust cuff pres-
sure also postoperatively and to omit the necessity
to repetitively activate the pump [87]. The twomost
recent studies report on long-term outcomes, dem-
onstrating persistent efficacy in 74% of patients up
to 10 years [88], and on the feasibility to implant the
AUS using the daVinci robot [89].
However, RCTs are actually lacking and the best
site for cuff placement inmale neurological patients
is still a matter of debate. In male neurological
patients, assessment of the ejaculatory status can
be relevant as AUS placement at the bladder neck
level may allow patients to achieve antegrade ejac-
ulation [83].
CONCLUSION
Management of urinary incontinence in male
neurological patients is challenging and will usually
require a combination of different treatment
options. Although the therapeutic armamentarium
has been increased during the last decades providing
new possibilities for clinicians and patients, the
level of evidence is often low. Moreover, current
findings are mainly from MS and SCI patients with-
out gender-specific outcomes limiting generaliz-
ation of the results.
The established cornerstones of neurogenic uri-
nary incontinence therapy, such as ISC, antimuscar-
inics, intradetrusor onabotulinumtoxinA injections,
augmentation cystoplasty, urinary diversion, and
AUS, have not substantially changed. There is a clear
interest in conservative and further minimally inva-
sive therapeutic options, such as neuromodulation,
either applied from external or via implantable devi-
ces, and suburethral suspension systems. Recent data
arepromisingbut further research isurgentlyneeded.
RCTs for assessing efficacy and safety of different
therapies for urinary incontinence in male neuro-
logical patients are a challenge and well designed
multicenter studies are highly warranted.
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